Nuclear medicine is one of the medical imaging modalities. It utilizes the use of radiopharmaceutical for the purpose of
diagnostic or therapeutic for the patient. The term of radiopharmaceutical consists of two main components which are radionuclide
and pharmaceutical. Radionuclide act as tracer which can be detected by the special camera while pharmaceutical often act as
ligand to bring the radionuclide to the targeted organ. In this study, Diethylenetriaminepentaacetic acid (DTPA) which is a
pharmaceutical that targeting kidney was being produced in the kit form by using freeze drying method to increase its stability and
shorten its preparation time before radiolabelling. The DTPA kit is radiolabelled with the 99mTc (t1/2 = 6 hours) to form 99mTc-DTPA
complex before injecting to the patient. Since this radiopharmaceutical is intended for the patient use, a thorough quality control
must be done to ensure its safety and efficacy. Certificate of Analysis (CoA) of DTPA kit that was obtained from Quality Control
Unit of Medical Technology Division, Malaysian Nuclear Agency proves the safety and efficacy of the kit to be legally supplied for
the patient use.
Key words: DTPA kit, Technetium-99m, Freeze drying, renal scintigraphy, pharmaceutical-grade
|
